4-8 Maple Street
London W1T 5HD
United Kingdom
44 20 3781 9360
https://www.benevolent.com
Sector(s): Healthcare
Industry: Biotechnology
Full-time employees: 248
Name | Title | Pay | Exercised | Year born |
---|---|---|---|---|
Dr. Joerg Moeller M.D., Ph.D. | CEO & Executive Director | N/A | N/A | N/A |
Dr. Ivan Griffin Ph.D. | Co-Founder | 350.38k | N/A | N/A |
Ms. Catherine Isted A.C.M.A. | Chief Financial Officer | N/A | N/A | 1975 |
Dr. James Malone | Chief Technology Officer | N/A | N/A | N/A |
Dr. Anne Phelan | Chief Scientific Officer & Site Head for the Benevolent Cambridge Laboratories | 354.06k | N/A | N/A |
Ms. Fleur Wood | Vice President of Investor Relations | N/A | N/A | N/A |
Mr. Will Scrimshaw | General Counsel & Company Secretary | N/A | N/A | N/A |
Ms. Anna Fullerton-Batten | Chief People Officer | N/A | N/A | N/A |
Mr. Tom Holgate | Senior Vice President of Finance | N/A | N/A | N/A |
Ms. Christina Busmalis | Chief Revenue Officer | N/A | N/A | N/A |
BenevolentAI S.A. operates as a clinical-stage artificial intelligence (AI) enabled drug discovery and development company. Its Benevolent platform integrates AI and science to uncover and develop drugs for complex diseases. The company's development pipeline includes BEN-8744, an oral phosphodiesterase 10 (PDE10) inhibitor under phase 1 study for the treatment of Ulcerative Colitis; BEN-28010, an oral brain penetrant CHK1 inhibitor under preclinical study for the treatment of Glioblastoma Multiforme; BEN-34712, a preclinical candidate for the potential treatment of ALS; and various candidates for the treatment of fibrosis and Parkinson's disease. It has collaboration agreements with AstraZeneca and Merck to enhance understanding of complex disease biology and identify new targets. The company was founded in 2013 and is headquartered in London, United Kingdom.
BenevolentAI S.A.’s ISS governance QualityScore as of N/A is N/A. The pillar scores are Audit: N/A; Board: N/A; Shareholder rights: N/A; Compensation: N/A.